New Drug Trial Shows Promise for Bowel Condition Ulcerative Colitis

The trial, known as ANTHEM-UC, examined icotrokinra as a potential therapy for ulcerative colitis (UC) — a long-term condition in which the lining of the large bowel becomes inflamed, causing symptoms such as urgent diarrhoea, stomach cramps, and bleeding. The findings were shared by the journal on social media this week.

Phase 2 trials are an early but meaningful stage of drug development — they test whether a treatment works and is safe in a defined group of patients, before larger studies begin. Icotrokinra is the subject of the ANTHEM-UC research, which falls under the field of gastroenterology, the branch of medicine dealing with the digestive system.

UC affects hundreds of thousands of people across the UK. It’s a form of inflammatory bowel disease (IBD) and, while it can be managed, there’s currently no cure. Many patients cycle through treatments over years, so any new option reaching clinical trial stage is watched closely by the medical community.

The New England Journal of Medicine is one of the world’s most widely read peer-reviewed medical journals. Publication there typically signals that a study has passed rigorous independent review.

The full trial results are available through the journal. Anyone experiencing symptoms of UC — persistent diarrhoea, blood in stools, or unexplained stomach pain — should speak to their GP in the first instance. Do not self-diagnose or adjust any existing medication without medical advice.

For general health concerns, NHS 111 is available by phone or online. In an emergency, call 999.